Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Immunovant, Inc. (IMVT)
Company Research
Source: GlobeNewswire
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP with pivotal study initiations for lead asset IMVT-1402 in these indications expected imminentlyImmunovant and Roivant to host combined investor call to discuss these updates today, March 19, 2025 at 8 a.m. EDT NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinica
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Immunovant (NASDAQ:IMVT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $28.00. They now have a "neutral" rating on the stock.MarketBeat
- Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]Seeking Alpha
- Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]Seeking Alpha
- Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 11/10/25 - Miss
IMVT
Sec Filings
- 12/19/25 - Form 4
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form 4
- IMVT's page on the SEC website